Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report)'s stock price was down 4.1% on Thursday . The company traded as low as $15.75 and last traded at $16.05. Approximately 7,439 shares changed hands during trading, a decline of 97% from the average daily volume of 292,863 shares. The stock had previously closed at $16.73.
A number of analysts have weighed in on TYRA shares. Oppenheimer increased their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an "outperform" rating in a research report on Thursday, September 19th. Wedbush reissued an "outperform" rating and set a $28.00 target price on shares of Tyra Biosciences in a research report on Friday, October 25th. Bank of America raised shares of Tyra Biosciences from a "neutral" rating to a "buy" rating and increased their target price for the company from $22.00 to $31.00 in a research report on Friday, October 18th. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Monday. Finally, UBS Group started coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a "buy" rating and a $28.00 target price for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences has a consensus rating of "Buy" and a consensus target price of $30.50.
Read Our Latest Analysis on TYRA
The company has a market cap of $817.70 million, a price-to-earnings ratio of -10.04 and a beta of 1.04. The firm's 50-day moving average price is $15.40 and its 200 day moving average price is $19.20.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.
In related news, Director Nina S. Kjellson sold 11,078 shares of Tyra Biosciences stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $16.17, for a total value of $179,131.26. Following the completion of the sale, the director now owns 472,207 shares of the company's stock, valued at approximately $7,635,587.19. This trade represents a 2.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Todd Harris sold 19,084 shares of Tyra Biosciences stock in a transaction on Monday, October 21st. The shares were sold at an average price of $27.90, for a total transaction of $532,443.60. Following the completion of the sale, the chief executive officer now directly owns 1,355,927 shares of the company's stock, valued at approximately $37,830,363.30. The trade was a 1.39 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,731 shares of company stock valued at $1,185,162. 15.40% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of TYRA. Janus Henderson Group PLC acquired a new stake in Tyra Biosciences in the 3rd quarter valued at $24,994,000. Perceptive Advisors LLC lifted its stake in Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company's stock valued at $16,108,000 after acquiring an additional 338,208 shares in the last quarter. Ally Bridge Group NY LLC bought a new position in Tyra Biosciences during the 2nd quarter valued at $4,232,000. Ensign Peak Advisors Inc bought a new position in Tyra Biosciences during the 2nd quarter valued at $3,047,000. Finally, American Century Companies Inc. lifted its stake in Tyra Biosciences by 582.9% during the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company's stock valued at $2,723,000 after acquiring an additional 145,346 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company's stock.
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.